Biokine: Motixafortide (BL-8040) Receives Orphan Drug Designation for the Treatment of Pancreatic Cancer in Europe – CBI
Homepage /  Press Release /  Biokine: Motixafortide (BL-8040) Receives Orphan Drug Designation for the Treatment of Pancreatic Cancer in Europe

Press Release

Biokine: Motixafortide (BL-8040) Receives Orphan Drug Designation for the Treatment of Pancreatic Cancer in Europe